Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 5:30 pm Purchase | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | Armistice Capital, LLC | 5,800,000 7.460% | 5,800,000 (New Position) | Filing History |
| 2025-02-14 4:42 pm Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | Paradigm BioCapital Advisors LP | 0 0.000% | -4,331,321 (Position Closed) | Filing History |
| 2025-02-13 8:15 pm Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | SUVRETTA CAPITAL MANAGEMENT, LLC | 5,198,189 6.700% | -2,274,154 (-30.43%) | Filing History |
| 2025-02-13 08:57 am Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | James E. Flynn | 0 0.000% | -5,312,733 (Position Closed) | Filing History |
| 2025-02-04 8:09 pm Purchase | 2025-01-27 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 5,912,554 7.500% | 2,504,500 (+73.49%) | Filing History |
| 2025-02-04 8:05 pm Sale | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 3,408,054 4.300% | -804,292 (-19.09%) | Filing History |
| 2025-01-08 7:42 pm Purchase | 2024-12-31 | 13G | Kura Oncology, Inc. KURA | BlackRock Inc. BLK | 7,934,104 10.200% | 618,457 (+8.45%) | Filing History |
| 2024-12-05 6:55 pm Purchase | 2024-11-27 | 13G | Kura Oncology, Inc. KURA | RA Capital Management, L.P. | 4,368,998 5.600% | 4,368,998 (New Position) | Filing History |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 4,212,346 5.400% | -3,160,882 (-42.87%) | Filing History |
| 2024-11-14 4:31 pm Purchase | 2024-09-30 | 13G | Kura Oncology, Inc. KURA | Paradigm BioCapital Advisors LP | 4,331,321 5.700% | 470,003 (+12.17%) | Filing History |
| 2024-05-02 4:34 pm Purchase | 2024-04-22 | 13G | Kura Oncology, Inc. KURA | Paradigm BioCapital Advisors LP | 3,861,318 5.100% | 3,861,318 (New Position) | Filing History |
| 2024-02-14 5:58 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | EcoR1 Capital LLC | 7,598,797 9.990% | 960,426 (+14.47%) | Filing History |
| 2024-02-14 09:39 am Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | BIOTECHNOLOGY VALUE FUND L P | 7,373,228 9.900% | 3,572,245 (+93.98%) | Filing History |
| 2024-02-13 5:23 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | SUVRETTA CAPITAL MANAGEMENT, LLC | 7,472,343 9.990% | 1,095,528 (+17.18%) | Filing History |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Kura Oncology, Inc. KURA | The Vanguard Group | 4,037,691 5.440% | 632,522 (+18.58%) | Filing History |
| 2024-02-12 5:33 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | James E. Flynn | 5,312,733 7.150% | 938,689 (+21.46%) | Filing History |
| 2024-01-24 2:27 pm Purchase | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | BlackRock Inc. BLK | 7,315,647 9.800% | 2,152,811 (+41.70%) | Filing History |
| 2024-01-23 09:12 am Sale | 2023-12-31 | 13G | Kura Oncology, Inc. KURA | STATE STREET CORP STT | 2,921,810 3.930% | -1,524,617 (-34.29%) | Filing History |
| 2023-09-21 4:55 pm Purchase | 2023-09-14 | 13G | Kura Oncology, Inc. KURA | James E. Flynn | 4,374,044 5.890% | 1,991,044 (+83.55%) | Filing History |
| 2023-02-14 09:32 am Sale | 2022-12-31 | 13G | Kura Oncology, Inc. KURA | AVORO CAPITAL ADVISORS LLC | 3,105,000 4.500% | -895,000 (-22.38%) | Filing History |